Companies: 10,795·Total market cap: $144.5T
LB Pharmaceuticals Inc Common Stock

LB Pharmaceuticals Inc Common Stock

LBRXNASDAQHealthcare● Active
$28.86
+$0.33(+1.15%)
Market Cap$827533617
P/E Ratio
52W High$33.47
52W Low$13.36
SEC Filings

LB Pharmaceuticals Inc Common Stock (LBRX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001691082 · LBRX · NASDAQ · as of Jun 8, 2026

Filing snapshot

113
Total Filings
4
Latest Form
2026-06-05
Most Recent
2025
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001691082 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-26
Fiscal Year End
Mar 26, 2026
Accession No.
0001193125-26-126368
Primary Document
lbrx-20251231.htm
Source: data.sec.gov · CIK 0001691082 · Accession 0001193125-26-126368

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-12
8-KCurrent Report
8-K
2026-05-12Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-13
View
424B3424B3
424B3
2026-05-12
View
10-QQuarterly Report
10-Q
2026-05-12
View
8-KCurrent Report
8-K
2026-05-12
View
ARSARS
ARS
2026-04-23
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-23
View
DEF 14AProxy Statement
DEF 14A
2026-04-23
View
EFFECTEFFECT
EFFECT
2026-04-14
View
424B3424B3
424B3
2026-04-14
View
CORRESPCORRESP
CORRESP
2026-04-10
View
UPLOADUPLOAD
UPLOAD
2026-04-10
View
S-1IPO Registration Statement
S-1
2026-04-06
View
Showing 1–15 of 87 filingsForm 4 / 144 hidden· 113 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001691082  |  Exchange: NASDAQ · Healthcare

LB Pharmaceuticals Inc Common Stock (NASDAQ: LBRX) has submitted 113 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2025. As a Healthcare sector company with CIK 0001691082, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is LB Pharmaceuticals Inc Common Stock's most comprehensive regulatory disclosure. The most recent LB Pharmaceuticals Inc Common Stock 10-K was filed on 2026-03-26 for fiscal year ending 2026. Historical LBRX 10-K annual reports are available from 2016 through 2026.

Investors researching LB Pharmaceuticals Inc Common Stock SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

LBRX SEC Filings · 8 questions

LB Pharmaceuticals Inc Common Stock (LBRX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 113 filings and access original documents at no cost. LB Pharmaceuticals Inc Common Stock's CIK is 0001691082.

LBRX SEC filingsLB Pharmaceuticals Inc Common Stock SEC documentsfind LBRX 10-K